Research goals: To elucidate the pathophysiology of psychiatric disorders which lead to suicide, including mood disorders and schizophrenia. These studies will be conducted by the examination of genetic and transcriptional variation in patients relative to comparison groups. Through these investigations, we aim to identify novel biochemical targets for improved psychotropic medication and biological markers to facilitate diagnosis.


  1. BOSTROM JA, SODHI MS. (2013) A Look to the Future: Epigenetics in Psychiatric Disorders and Treatment. In: Lam YWF, Cavallari LH (eds). Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. Elsevier Inc: Maryland Heights, MO. p.225-246.
  2. HANSON R, GANNON M, KHAMO N, SODHI MS, ORR A, STUBBINGS J (2013). Improvement in Safety Monitoring of Biologic Response Modifiers After the Implementation of Clinical Care Guidelines by a Specialty Pharmacy Service in an Academic Health System. J Managed Care Pharmacy, 19 (1): 49-67. PMID: 23383700.
  3. SODHI MS, SIMMONS M, MCCULLUMSMITH R, HAROUTUNIAN V, MEADOR-WOODRUFF JH (2011). Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia. Biological Psychiatry 70:646-654. PMID: 21549355. [Link]
  4. SIMMONS M, MEADOR-WOODRUFF JH, SODHI MS (2010). Increased cortical expression of an RNA editing enzyme occurs in major depressive suicide victims. Neuroreport 21(15):993-7.PMID: 20802353. [Link]
  5. ROTH TL, LUBIN FD, SODHI M, KLEINMAN JE (2009). Epigenetics and schizophrenia. Biochim Biophys Acta;1790(9):869-77. PMID: 19559755 Times cited=37. [Link]
  6. SODHI M, WOOD KH, MEADOR-WOODRUFF J (2008). Role of glutamate in schizophrenia: integrating excitatory avenues of research. Exp Review Neurother 8(9), 1389-1406. PMID:18759551 Times cited=23. [Link]
  7. HACKLER EA, AIREY DC, SHANNON CC, SODHI MS, SANDERS-BUSH (2006). 5-HT2C receptor RNA editing in the amygdala of inbred strains: implications for anxiety and fear. Neurosci Res 55(1):96-104. PMID: 16580757 Times cited=36. [Link]
  8. SODHI MS, AIREY DC, LAMBERT W, BURNET PW, HARRISON PJ, SANDERS-BUSH E (2005). A rapid new assay to detect RNA editing reveals antipsychotic-induced changes in serotonin-2C transcripts. Mol Pharmacol 68: 711-719. PMID: 15917433 Times cited=28. [Link]
  9. POOLEY EC, FAIRBURN CG, COOPER Z, SODHI MS, COWEN PJ, HARRISON PJ (2004). A 5-HT2C receptor promoter polymorphism (HTR2C - 759C/T) is associated with obesity in women, and with resistance to weight loss in heterozygotes. Am J Med Genet (Neuropsychiat Genet). 126B: 124-7. PMID: 15048662 Times cited=50. [Link]
  10. SODHI MS, SANDERS-BUSH E (2004). Serotonin and brain development. Int Rev Neurobiol. 2004;59:111-74. PMID:15006487 Times cited=122. [Link]
  11. TUNBRIDGE, E., P. W. BURNET, SODHI MS, HARRISON PJ (2004). "Catechol-o-methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression." Synapse 51(2):112-8. PMID: 14618678 Times cited=50. [Link]
  12. SODHI MS, BURNET PJ, MAKOFF AJ and HARRISON PJ (2001). Reduced mRNA editing of the human 5-HT2C receptor in schizophrenia. Molecular Psychiatry, 6 (4), 373-9. PMID: 11443520 Times cited=109. [Link]
  13. ARRANZ MJ, MUNRO J, BIRKETT J, BOLONNA A, MANCAMA D, SODHI MS, et al. (2000). Pharmacogenetic prediction of clozapine response. Lancet 355: 1615 - 1616. PMID: 10821369 Times cited=196. [Link]
  14. ARRANZ MJ, ERDMANN J, KIROV G, RIETSCHEL M, SODHI M, et al. (1997). 5-HT2A receptor and bipolar affective disorder: Association studies in affected patients. Neurosci Lett 224 (2): 95-98. PMID:9086465 Times cited=46. [Link]
  15. SODHI MS (2000). The role of the 5-HT2 serotonin receptor subtypes in psychosis: a pharmacogenetic study. Thesis, Kings College, University of London, U.K.
  16. SODHI MS, MURRAY RM (1997). Future therapies for schizophrenia. Expert Opinion on Therapeutic Patients 7(2): 151-165. Times cited=7.[Link]
  17. COLLIER D, ARRANZ M, SHAM P, BATTERSBY S, GILL P, AITCHISON KJ, SODHI MS, et al. (1996). The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. NeuroReport 7(10):1675-1679. PMID: 8904780 Times cited=149.[Link]
  18. ARRANZ MJ, COLLIER DA, MUNRO J, SHAM P, KIROV G, SODHI MS, ROBERTS GW, PRICE J, AND KERWIN RW (1996). Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neuroscience Letters 217:177-178. PMID:8916101 Times cited=81.[Link]
  19. SODHI MS, ARRANZ MJ, CURTIS DA, SHAM PC, BALL DM, ROBERTS GW, PRICE J, COLLIER DA AND KERWIN RW (1995). Association between clozapine response and allelic variation in the 5-HT2C receptor gene. NeuroReport 7(1): 169-172. PMID: 8742444 Times cited=135. [Link]
  20. ARRANZ MJ, COLLIER D, SODHI MS, BALL DM, ROBERTS GW, PRICE J, SHAM P AND KERWIN R (1995). Association between clozapine response and allelic variation in the 5-HT2A receptor gene. Lancet, 346: 281-282. PMID: 7630250 Times cited=268 [Link]


Important Dates

3/14/13: CPB & Pharmacy Practice Seminar: "Estrogen, Depression, and Hippocampal Function". Lori L. McMahon, PhD. 12PM, 3rd Floor Library MBRB.

4/18/13: CPB & UICENTRE Seminar "Allosteric Modulators of GPCRs as a Novel Approach to Treatment of CNS Disorders". Jeff Conn, PhD. 12PM, 3rd Floor Library MBRB.

5/02/13: CPB & Pharmacy Practice Seminar "Genetic Variation and Alternative Transcripts in Human Brain Development and Schizophrenia". Joel E. Kleinman, PhD. 12PM, 3rd Floor Library MBRB.

9/12/13: CPB Seminar "Effects of G-Protein Coupled Receptors on Vessicle Fusion". Simon Alford, PhD. 12PM, 3rd Floor Library MBRB..

9/19/13: CPB Seminar "TBD". Janet Richmond, PhD. 12PM, 3rd Floor Library MBRB.

11/09/13-11/13/13: Society for Neuroscience Annual Meeting; San Diego, CA.